Document is current
Any future updates will be listed below
-
Authors
Pinto-Marín, Álvaro https://orcid.org/0000-0002-4719-053X
Trilla-Fuertes, Lucía https://orcid.org/0000-0002-4452-3474
Miranda Poma, Jesús
Vasudev, Naveen S. https://orcid.org/0000-0001-8470-7481
García-Fernández, Eugenia
López-Vacas, Rocío
Miranda, Natalia
Wilson, Michelle
López-Camacho, Elena
Pertejo, Ana
Dittmann, Antje
Kunz, Laura
Brown, Joanne
Pedroche-Just, Yaiza
Zapater-Moros, Andrea
de Velasco, Guillermo
Castellano, Daniel
González-Peramato, Pilar
Espinosa, Enrique
Banks, Rosamonde E. https://orcid.org/0000-0002-0042-8715
Fresno Vara, Juan Ángel
Gámez-Pozo, Angelo
- License Information
-
More Information
Article History
Received: 4 November 2024
Revised: 18 March 2025
Accepted: 28 March 2025
First Online: 7 May 2025
Competing interests
: AP: Research funding: Pfizer, BMS Advisory boards: Pfizer, Novartis, Ipsen, BMS, Janssen, Astellas, Sanofi, Bayer, Clovis, Roche, MSD, Pierre Fabre, Merck Clinical trial payments: Pfizer, Bayer, Janssen, MSD, Clovis, Pharmacyclics, BMS, Sanofi, Astra Zeneca, Roche, Eisai, Aveo. Travel arrangements: Janssen, Roche, Pfizer, BMS, Ipsen. EE: Biomedica Molecular Medicine Shares, Bio-miR patent, Courses: BMS, MSD, Pierre Fabré and Novartis. AGP: Biomedica Molecular Medicine Shares, Bio-miR patent. JAFV: Biomedica Molecular Medicine Shares, Bio-miR patent. NV: Research funding: BMS Advisory boards: BMS, Pfizer, Merck Speaker fees: Ipsen, BMS, Eisai, EUSA pharma.
: In all cases, written informed consent was obtained from patients and ethical approvals were obtained, specifically Hospital Doce de Octubre Ethical Committee (17/214) for the discovery cohort, Leeds East Research Ethics Committee (20/YH/0103) for the Leeds validation cohort and Hospital La Paz Ethical Committee (PI-3310) for the Spanish validation cohort. All methods were performed in accordance with the relevant guidelines and regulations.
